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Steroidogenic factor (SF1) is an orphan nuclear receptor that is essential for 
steroid hormone-biosynthesis and endocrine development.  Recent studies have 
demonstrated that phospholipids are ligands for SF1.  In the present study our aim was to 
identify endogenous ligands for SF1 and characterize their functional significance in 
mediating cAMP-dependent transcription of human CYP17.  Using mass spectrometry 
we show that in H295R adrenocortical cells SF1 is bound to sphingosine (SPH) under 
basal conditions and that cAMP stimulation decreases the amount of SPH bound to the 
receptor.   We also show that silencing both acid and neutral ceramidases using siRNA 
induces CYP17 mRNA expression, suggesting that SPH acts as an inhibitory ligand.  In 
vitro analysis of ligand binding using scintillation proximity assays show that several 
sphingolipids and phospholipids, including phosphatidic acid (PA), can compete with 
[3H]SPH for binding to SF1, suggesting that SF1 may have more than one ligand and 
binding specificity may change with the changes in intracellular fluxes of phospholipids.  
Further, phosphatidic acid (PA) induces SF1-dependent transcription of CYP17 reporter 
constructs. Inhibition of diacyglycerol kinase (DAGK) activity using R59949 and 
silencing DAGK-θ expression attenuates SF1-dependent CYP17 transcriptional.  We 
propose that PA is an activating ligand for SF1 and that cAMP-stimulated activation of 








1.1 Theoretical Background on Steroidogenesis & Cytochrome P450 Enzymes  
 Steroid hormones are ubiquitous regulators of wide variety of physiological 
processes. They are derivatives of cholesterol and are synthesized in a variety of organs, 
including the adrenal gland and gonads. Steroid hormone biosynthesis requires a battery 
of oxidative enzymes located in both mitochondria and endoplasmic reticulum.   These 
enzymes are members of the cytochrome P450 superfamily and steroid dehydrogenases  
(HSD) and are transcriptionally regulated by a cAMP/cAMP-dependent protein kinase 
(PKA) pathway. 
P450 side chain cleavage enzyme (P450scc) is the enzyme that catalyzes the first 
and rate limiting step in steroidogenesis. Within mitochondria, P450scc converts 
cholesterol to pregnenolone [1, 2]. Pregnenolone itself is not a hormone, but is the 
precursor for the synthesis of all of the steroid hormones. Conversion of cholesterol to 
pregnenolone takes place in three successive monooxygenation reactions: 1) 
Hydroxylation of C-22, 2) hydroxylation of C-20, 3) cleavage of the C-20 & 22 bond. 
P450scc is expressed in all three zones of the adrenal cortex, in th leydig cells of testis, 
and in the theca interna of ovary In addition to steroidogenic tissues, the expression of 
P450scc has been detected in the brain, but at levels that are more than an order of 
magnitude lower.  
3β hydroxysteroid dehydrogenase (3β-HSD) has two major catalytic activities 
which in concert, convert 3β-hydroxy-5-ene steroids into 3-keto-4-ene steroids[3]. In 
humans, rat and mouse there are at least 2 or 3 homologous genes encoding 3β-HSD, as 
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opposed to single genes encoding P450 enzymes. 3β-HSD is localized in the same 
steroidogenic cells as P450scc: in all three zones of the adrenal cortex, in the interstitial 
Leydig cells of the testis, in the theca interna and corpora lutea of the ovary[3]. 
P450c17 catalyzes two key reactions: 1) 17α-hydroxylation of C21 progesterone 
and pregnenolone, and 2) cleavage of the C17-C20 bond of C21 steroids[4]. The 17α-
hydroxylation is a required step in glucocorticoid biosynthesis, whereas the C17-C20 
bond side chain cleavage is essential for the biosynthesis of androgens. 
Immunohistochemical analysis of the adrenal gland has shown that P450c17 is present in 
the zona fasiculata and reticularis but not in zona glomerulosa [5]. This observation is 
consistent with the role of zona glomerulosa as the site of mineralocorticoid biosynthesis 
where 17α-hydroxylation is not a required activity. Like all steroidogenic genes, 
induction of the gene that encodes P450c17, CYP17, is mediated by cyclic AMP 
(cAMP). In human CYP17 gene, the homeo-domain protein Pbx 1 was shown to interact 
with protein kinase A in the cAMP-dependent regulation of CYP17 [6]. Further it has 
been demonstrated that transcriptional activation of human CYP17 in adrenal cells 
depends on complex formation among p54(nrb)/NonO, protein-associated splicing factor, 
and SF-1, which also participates in repression of transcription  [7]. 
P450c21 enzyme is involved in the 21-hydroxylation of progesterone and 17-
hydroxy-progesterone, yielding deoxycorticosterone and 11-deoxycortisol from the two 
substrates, respectively. The 21-hydroxylation step is an important step in the synthesis of 
gluco- and mineralocorticoids , and the deficiencies in these enzymes lead to salt wasting 
syndrome and congenital adrenal hyperplasia [8]. The major site of expression of 
P450c21 is the adrenal cortex, however low levels of P450c21 have been observed in 
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human lymphocytes and brain[9].Both P450c21 and P450c17 are regulated by 
adrenocorticotropin (ACTH) [10]. 
 Conversion of testosterone into 17β-estradiol is catalyzed by aromatase 
(P450arom). In the ovary P450arom is expressed in granulosa cells, which is the major 
site of estrogen production in females [11]. However, this enzyme is widely expressed in 
many tissues such as breast, central nervous system, skin and placenta [12]. The gene 
encoding P450arom is the longest one among steroidogenic P450 genes, and is unique 
because it utilizes alternative promoters in a tissue specific manner. 
 17-hydoxy steroid dehydrogenase (17β-HSD),  also referred as 17-keto-steroid 
reductase, catalyzes the reversible conversion of the 17-keto and 17β-hydroxy groups in 
androgens and estrogens, including androstenedione, dehydroepiandrosterone (DHEA), 
and 17β-estradiol [13]. This enzyme is expressed in the testis in Leydig cells of the 
interstitial tissue, and in the ovary, in theca interna, but not in granulosa cells or corpus 
luteum.  
In the adrenal cortex, steroidogenesis in regulated both acutely (within minutes) 
and chronically (hours to days) by ACTH hormone. The chronic regulation is at the level 
of transcription of steroidogenic genes whereas acute regulation is mediated by 
facilitating the movement of cholesterol into the mitochondria. Both the acute and 








Figure 1: Steroidogenesis Pathway 
 This figure shows steps in steroidogenesis leading to production of Progesterone, 
Aldosterone, Cortisol, Testosterone and Estradiol.  DHEA : Dehydroepiandrosterone, 





1.2 Nuclear Receptors: 
 The nuclear receptor super family is an evolutionarily related group of 
transcription factors that regulate genes involved in a variety of physiological, 
developmental, and metabolic processes [14]. Nuclear receptors  play  roles in regulation 
of reproductive system by steroid hormones [15], control of development by thyroid and 
retinoid hormones and regulation of bile acid by cholesterol biosynthesis.  Loss of 
nuclear receptor signaling, contributes to the development of endocrine related diseases 
such as breast cancer, ovarian cancer, prostrate cancer, diabetes and obesity. 
1.21   Classification and Characterization of Nuclear Receptors 
Steroid hormones were known to exist since the early 20th century, but the 
concept of high affinity, tissue-specific, steroidophilic factors - receptors - as mediators 
of hormone function, gained credence from pioneering tissue-binding studies by Elwood 
Jensen, Jack Gorski, Anthony Means and other pioneers in the field [16]. By the end of 
the 1980’s, the steroid and thyroid hormone receptors were first cloned and were found to 
exhibit extensive homology. This observation led to the discovery of other similarly 
structured receptors. Building upon biochemical evidence for the DNA binding and 
hormone binding activities of receptors, comparative alignment of the deduced amino 
acid sequences of the newly cloned receptor cDNAs indicated a modular organization of 
discrete motifs in each molecule, indicating a potential common ancestry and mode of 
action. As shown in figure 2, this superfamily contains not only ligand activated 
receptors, but large number of nuclear receptors that have been identified through 
sequence similarity to the known receptors, but have no identified ligand. These receptors 
are known as “orphan nuclear receptors”. During recent years, specific ligands and also 
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target genes and physiological functions have been elucidated for many orphan nuclear 
receptors, and therefore are now called “adopted nuclear receptors” [17]. Many of these 
newly identified ligands are lipid molecules, and their nuclear receptors function as lipid 
sensors that respond to cellular lipid levels and elicit gene expression changes to maintain 
metabolic and structural homeostasis. 
Although nuclear receptors are extremely diverse with regards to their ligands, 
they share common structural organization. The N-terminal region (A/B domain) is 
highly variable, and contains at least one constitutively active transactivation region (AF-
1) and several autonomous transactivation domains (AD); A/B domains are variable in 
length, from less than 50 to more than 500 amino acids, and their 3D structure is not 
known. The most conserved region is the DNA-binding domain (DBD, C domain), which 
notably contains the P-box, a short motif responsible for DNA-binding specificity on 
sequences typically containing the AGGTCA motif, and is involved in dimerization of 
nuclear receptors. Between the DNA-binding and ligand binding domains is a less 
conserved region (D domain) that behaves as a flexible hinge between the C and E 
domains, and contains the nuclear localization signal (NLS), which may overlap on the C 
domain. The largest domain is the moderately conserved ligand-binding domain (LBD, E 
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Figure 2: Classification of Nuclear receptor 
Nuclear receptors can be subdivided into three or four groups, depending on the source 
and type of their ligand. Receptors with known physiological ligands are shown in color, 
and current orphan receptors are shown in gray. The first group is represented by classic 
nuclear steroid hormone receptors. Members of this group include the glucocorticoid 
(GR), mineralocorticoid (MR), estrogen (ER), androgen (AR), and progesterone (PR) 
receptors. The second nuclear receptor paradigm is represented by the adopted orphan 
nuclear receptors that function as heterodimers with the retinoid X receptor (RXR). 
Orphan receptors become adopted when they are shown to bind a physiological ligand. In 
contrast to the endocrine steroid receptors the adopted orphan receptors respond to 
dietary lipids. In addition to the adopted orphan receptors, there are four other RXR 
heterodimer receptors that do not fit precisely into either group. These include the thyroid 
hormone (TR), retinoic acid (RAR), vitamin D (VDR), and ecdysone (EcR) receptors. 
The ligands for these four receptors and the pathways they regulate employ elements of 
both the endocrine and lipid-sensing receptor pathways. The last group is of orphan 
nuclear receptors, whose ligands are unidentified.  
 




1.3   Steroidogenic Factor 1 (SF1) 
SF1 is a member of the nuclear receptor family of proteins that share high homology with 
the Drosophila protein fushi tarazu factor-1 (FTZ-F1), a regulator of embryogenesis and 
metamorphosis [19]. SF1 is classified as a nuclear receptor on the basis of its structural 
homology and functional similarity with many members of this family of proteins. It has 
a zinc finger DNA binding domain, an intervening hinge region, and a carboxy-terminal 
putative ligand binding domain (LBD). However, SF1 belongs to the subgroup of nuclear 
receptors that are distinguishable for three reasons: 1) SF1 differs structurally from most 
other nuclear receptors, as it lacks an amino-terminal (A–B) domain, 2) unlike other 
nuclear receptors SF1 binds to its cognate DNA response element as a monomer, 3) SF1 
belongs to the subgroup of nuclear receptors that are termed orphan nuclear receptors due 
to the absence of a bona fide ligand which can activate SF1 dependant gene transcription 
[20]. Increased expression of SF1 in steroidogenic cells and its very high homology to 
Drosophilla protein FTZ-F1 indicates the role of SF1 as an important regulator in 
mammalian steroidogenesis.  
Studies carried out on SF1 knock out mice indicate that SF1 plays an important role in 
reproductive development (Figure 4). Studies using SF1+/- mice have established that 
SF1 is not essential for prenatal survival, as SF1 haplo-insufficient mice are born at a 
normal Mendelian frequency. SF1 null mice have neither adrenal glands, nor male or 
female gonads, since adrenocortical and gonadal precursor cells assemble in the 











Figure 3: The structure of steroidogenic factor 1 (SF1), compared with the general 
structure of nuclear receptors 
In addition to the shared DNA-binding domain (DBD), most receptors contain two 
activation function (AF) domains. SF1 lacks a functional AF-1, and its transcriptional 
activation function resides within its C-terminal region, which harbours the conserved 
AF-2 hexamer. A repression (R) domain is adjacent to the AF-2 hexamer, and a proximal 
interaction domain (PID) is located closer to the DBD. Serine-203 residue is a target for 
phosphorylation (P) by MAP kinases. A region C-terminal to the DBD, which includes 
proline-rich (Pro) sequences, mediates interaction with transcription factor IIB (TFIIB) 
and c-Jun. 
  












Figure 4: Phenotype of SF1 Knock out mice. 
A. SF1 -/- female mouse lacks adrenal glands and ovary. 
B. SF1 +/+ female mouse with normal adrenal gland and oviduct. 
C. SF1 -/- male mouse lacks epididymis and testis. 
D. SF1 +/+ male mouse with normal epididymis and testis. 
                      






As gonads fail to develop in SF1 null mice, genotypically SF1 null mice exhibit sex 
reversal. Studies showing the diminished expression of β subunit of Leutinizing Hormone 
and follicle stimulating hormone in SF1 -/- mice demonstrate that SF1 is critical 
component of endocrine tissue development  [21, 22].  
SF1 regulates the expression of all genes that encode steroidogenic enzymes and 





Figure 5: Promoter elements that mediate the effect of steroidogenic factor 1 (SF1) 
on important endocrine and reproductive targets. 
HSD: hydroxyl-steroid dehydrogenase; StAR: steroidogenic acute regulatory protein; 
MIS: Müllerian inhibitory substance; ACTH: adrenocorticotrophic hormone; SR-BI: 













Figure 6: The human SF1 (hSF1) structure complexed with phospholipids (A & B) 
Residues of the hSF1 ligand-binding pocket (stick models colored yellow and by atom 
type),showing salt bridge and hydrogen bonds(dotted lines) to the Phosphatidyl 










These studies led the researchers to postulate that SF1 activates gene expression 
in a ligand independent manner. However, recent x-ray crystallographic studies (Fig 6) 
carried out independently by three laboratories have shown that phospholipids are ligands 
for SF1 [23-25].   Specifically, Krylova, et al., have demonstrated that phosphatidyl 
inositols specifically interact with the ligand binding domain (LBD) of SF1 and that 
ligand binding is required for maximal activity of the receptor [23].   Li et al. found that 
receptor was shown to have a large (approximately 1600 Å) LBD that interacts with 
phospholipids that have fatty acid side chains between twelve and eighteen carbons [24].    
Moreover, the conformation established by the ethanolamine moiety on the 
phosphatidyl ethanolamine (PE) identified suggested that phospholipids with other head 
groups might also bind to SF1 [24].   Significantly, the large binding pocket led the 
authors to speculate that SF1 may readily exchange its ligands to respond to different 
phospholipids species [24].   
The central hypothesis of the present study was to identify endogenous ligands 
bound to SF1and characterize the functional significance of these molecules in mediating 
cAMP-dependent transcription of human CYP17 in the adrenal cortex. To test this 
hypothesis, mass spectrometry was used to identify molecules bound to SF1 purified 
from control or cAMP-stimulated H295R human adrenocortical cells. The effect of 
various lipids on SF1 was examined using a reporter gene assay and real time RT-PCR. 
Site- directed mutagenesis was used to mutate amino acids in the LBD of SF1 and these 
mutants were used to determine amino acids critical for ligand binding. Finally RNA 
interference (RNAi) was used to modulate cellular pools of ligand, in order to determine 
the effect on the ability of SF1 to activate CYP17 transcription.  
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CHAPTER2 
MATERIALS AND METHODS 
2.1 Reagents. 
Dibutyryl cAMP (Bt2cAMP) was obtained from Sigma (St. Louis, MO).   
Phospholipids and sphingolipids were obtained from Avanti Polar Lipids, Inc.  
(Alabaster, AL).  PA (egg yolk) was dissolved in chloroform, dried under nitrogen gas 
and resuspended in 50 mM Tris-HCl, pH 7.4 by ultrasonication.  The diacylglycerol 
kinase inhibitor 3-2,3-dihydro-2-thioxo-4(1H)quinazolinone (R59949) [26] was obtained 
from EMD Biosciences, Inc. (La Jolla, CA).  
2.2 Cell Culture. 
H295R adrenocortical cells [27, 28] were generously donated by Dr.  William E.  
Rainey (University of Texas Southwestern Medical Center, Dallas, TX) and cultured in 
Dulbecco's modified Eagle's/F12 (DME/F12) medium (Invitrogen, Carlsbad, CA) 
supplemented with 10% Nu-Serum I (BD Biosciences, Palo Alto, CA), 0.5% ITS Plus 
(BD Biosciences, Palo Alto, CA), and antibiotics.  Jeg3 human choriocarcinoma cells 
were obtained from Dr. Michael R. Waterman (Vanderbilt University School of 
Medicine, Nashville, TN) and cultured in DMEM medium containing 10% fetal bovine 
serum and antibiotics.  
2.3 Immunoprecipitation. 
For IP assays, H295R cells (150 mm dishes) were transfected with 45µg of mutant or 
wild type SF1-pCMV Tag1 per dish and treated with 1mM Bt2cAMP for 4 h.  Nuclear 
proteins were isolated using the NE-PER nuclear and cytoplasmic extraction reagent 
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(Pierce, Rockford, IL) and incubated with anti-SF1 (Upstate, Lake Placid, NY) or anti-
FLAG M2 antibody (Stratagene, La Jolla, CA) and protein A/G agarose beads (Santa 
Cruz Biotechnology, Santa Cruz, CA) overnight at 4 °C with rotation.   The mixture was 
then centrifuged, the supernatant removed, and the precipitant subjected to a series of 5-
minutes washes.   Agarose beads were washed three times with a modified RIPA buffer 
(150 mM NaCl, 50 mM Tris-Cl, pH 8.0, 5 mM EDTA, 0.5% sodium deoxycholate, 0.1% 
SDS, 0.2 mM phenylmethylsulfonyl fluoride, 10 µg/ml aprotinin, 10 µg/ml pepstatin, and 
10 µg/ml leupeptin) and five times with PBS.   The samples were then analyzed by mass 
spectrometry for detection of lipids and by SDS-PAGE (10% gel) and Western blotting to 
confirm SF1 expression. 
2.4 Analysis of sphingolipid and phospholipid molecular species. 
For sphingolipid measurements, immunoprecipitated SF1 was analyzed by liquid 
chromatography, electrospray ionization, tandem mass spectrometry (LC-ESI-MS/MS) as 
described previously [29, 30].  The internal standards for quantifying the amount of 
sphingolipid species bound to the receptor were obtained from Avanti Polar Lipids 
(Alabaster, AL).Briefly 0.5ml of methanol and 0.25ml of chloroform with internal 
standards was added to the immunoprecipitated SF1. Internal standards include 0.5nmol 
of each C12-SM, C12-Cer, C12-GlcCer, C12-LacCer, C20-SPH, C20-Sa, C17-
Sphingosine 1-phosphate, & C17-Sphinganine-phosphate. The pellet was sonicated and 
incubated overnight at 48ºC in a heating block. The sample was cooled and 75µl of 1M 
KOH in methanol was added, sonicated and incubated for 2h at 37ºC. Four hundred 
micro liter of sample was saved for MS/MS analysis of sphingoid bases, sphingoid 1-P, 
and Cer-P. Remaining sample was neutralized with 3µl of glacial acetic acid. After 
adding 1ml of chloroform and 2ml of water saple was mixed well and centrifuged. The 
upper layer was removed leaving the interface. The solvent and water was removed form 
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the lower layer using speed vac and MS/MS s was carried out for complex sphingolipids 
in this fraction. The sample saved for sphingoid bases was dried in the same way. The 
samples were loaded onto appropriate HPLC columns that are directly coupled to the ion 
source of a tandem mass spectrometer. The mass spectrometer was programmed to 
monitor specific, individually optimized precursor and product ion pairs in specific time 
frames. The signal generated by each ion transition uniquely identifies molecular species 
by retention time, mass, and structure. Furthermore, quantification was achieved by direct 
correlation of the peak areas generated by the internal standards with those of the 
endogenous species. Ionization and dissociation (collision energy) conditions were 
optimized for individual molecular species. 
2.5 Molecular modeling. 
Docking of Sphingosine (SPH) and Phosphatidic acid (PA) (34:1 and 36:1) into the 
ligand binding pocket of the published crystal structure of SF1 [24] was done using the 
INSIGHTII module of AFFINITY (Accelrys, San Diego, CA. A general method was 
developed for docking ligands into the binding pocket of the SF1 LBD crystal structure.  
After obtaining the coordinates of the crystal structure from the Protein Databank, it was 
prepared for docking. First SF1 LBD and the its associated ligand PE were unmerged. 
Hydrogen atoms were added to the entire SF1 LBD using a pH of 7.4 to determine the 
charge state of amino acid side chains.  The protein was “soaked” in a 5 Å layer of water 
so that the docking is performed in explicit solvent.  Soaking is accomplished by placing 
the protein in the center of an equilibrated box of water followed by removing water 
molecules that either contact atoms in the protein or are further than 5 Å from the protein. 
Affinity applies molecular mechanics in searching for and evaluating docked structures. In 
order to make the search fast enough for practical applications, the ligand/receptor system 
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is partitioned into “bulk” and “movable” atoms. Bulk atoms are defined as atoms of the 
receptor that are not in the defined binding site. These atoms are held rigid during the 
course of the docking search. Movable atoms consist of atoms in the binding site of the 
receptor and ligand atoms. These atoms can move freely, except for binding site atoms 
close to bulk atoms. For docking, the ligand is manually placed in the binding site of the 
protein by superimposing atoms of the ligand to be docked onto atoms of the 
crystallographic PE. The amino acids within 5 Å of the placed ligand are defined as the 
“binding site”; these are allowed to move during the docking process. You can define the 
binding site as residues which are within 5Å of the ligand, if the ligand is already in the 
binding site or if you are studying docking of a novel ligand whose binding site to the 
receptor is unknown, you can use the binding site of a known ligand for the new ligand. 
Hydrogen bond donors and acceptor atoms are defined for both the ligand and atoms 
within 5 Å of the placed ligand.  Torsions are also defined for the ligand.  A Monte-Carlo 
simulation is used to generate possible binding modes of the ligand-protein pair.  The 
ligand is randomly translated and rotated in the x, y, and z dimensions and the torsions 
are rotated to generate a new, random ligand placement.  The resulting structure is 
minimized and the energy of the new structure is compared to the previous structure.  If 
the energy of the new structure is lower than the energy of the previous structure, the new 
structure is accepted.  If the energy of the new structure is greater than the energy of the 
previous structure, it will be accepted if the energy is within a predefined energy range. 
The final step is to calculate the ligand-receptor interaction energies for each accepted 
and minimized structure.  Discover is used to calculate the van der Waals and 
electrostatic energies.  These energies can be used to compare the docked structures.   
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2.6 Bacterial expression of SF1. 
 PCR was used to add 6 histidine residues to the LBD of SF1 and the PCR product 
cloned into the pET17b vector (Novagen, Madison, WI).   The construct was transformed 
into BL21 cells and the cultures grown until the OD600nm equaled 0.4.   Isopropyl-beta-D-
thiogalactopyranoside (0.4 mM) was added and the cultures grown for 6 h at 28°C.   His-
tagged SF1 was purified using nickel affinity chromatography using a His-Bind 
purification kit (Novagen, Madison, WI).  Expression was verified by SDS-PAGE and 
MALDI-TOF (matrix-assisted laser desorption/ionization-time of flight) mass 
spectrometry. 
2.7 Scintillation proximity binding assay. 
Scintillation proximity assays [31, 32] were carried out using purified and 
biotinylated SF1.  SF1 (500 nM) was biotinylated using a EZ-Link Sulfo-NHS-LC-
biotinylation kit (Pierce, Rockford,IL) for two hours at 4ºC, with rotation.  The reaction 
was desalted to remove non-reacted biotinylation reagent as per the manufacturer’s 
instructions.  Streptavidin-PVT SPA beads (Amersham Biosciences, Piscataway, NJ) 
were suspended in assay buffer (50 mM Tris-Cl, pH 8.0, 50 mM KCl, 1 mM EDTA, 1 
mM CHAPS, 1 mM DTT, 0.1 mg/ml BSA) at 0.5 mg/ml.  The biotinylated receptor was 
added to a final concentration of 50 nM and the mixture incubated for four hours at 4ºC, 
with rotation.  
 The reaction was centrifuged at 4,000 rpm for 10 minutes and the uncoupled receptor 
(supernatant) was removed.  The beads were resuspended in assay buffer, incubated for 
15 minutes and centrifuged again.  Beads were resuspended in 1 ml assay buffer and 
stored at 4ºC until use.  For competition experiments, lipids obtained from Avanti Polar 
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Lipids (Alabaster, AL) were added at concentrations ranging from 0.1nM to 100 µM to 
reactions containing 10 nM [3H]-SPH.  Vials were incubated for 2 h at room temperature 
followed by scintillation counting.  All assays were performed at least three times in 
triplicate.  
2.8 Transient transfection and reporter gene analysis. 
To determine effect of mutations in the LBD on SF1-dependent transcriptional 
activity Jeg3 human choriocarcinoma cells (lack endogenous SF1)were sub-cultured onto 
12-well plates and 24 h later transfected with 250 ng of hCYP17 57-pGL3 reporter 
plasmid [33] and 100 ng of wild type or mutant (H310A, G341K, Y436A, K440D) SF1-
pCMV Tag1 (Invitrogen, Carlsbad, CA) using GeneJuice (Novagen, Madison, WI).   
Wild type SF1 was obtained from Ken-ichiro Morohashi, (National Institute for Basic 
Biology, Okazaki, Japan) and cloned into the pCMV Tag1 vector.  Mutants were 
prepared by using a QuikChange site-directed mutagenesis kit (Stratagene,La Jolla, CA) 
and were confirmed by sequencing.  Cells were co-transfected with 10 ng of the Renilla 
luciferase plasmid (phRL, Promega, Madison, WI) for normalization. Twenty-four h after 
transfection the cells were treated with 1 mM Bt2cAMP for 6 h and the transcriptional 
activity of the CYP17 reporter gene determined using a dual luciferase assay (Promega, 
Madison, WI).  
To examine the effect of sphingolipids and phospholipids on SF1-dependent CYP17 
reporter gene activity, Jeg3 human adrenocortical cells were transfected with 250 ng 
CYP17 57-pGL3, 100 ng SF1-pCMV Tag1, and 10 ng of the Renilla luciferase plasmid 
(for normalization).  Twenty-four hours after transfection cells were treated for 6 h with 1 
mM Bt2cAMP or PA (1 nM to 1 µM).  The role of DAGK in cAMP-dependent CYP17 
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transcription was examined by transfecting H295R cells with 250 ng CYP17 57-pGL3 for 
24 h followed by treatment with 1 mM Bt2cAMP and R59949 (DAGK inhibitor) for 6 h 
and harvested for dual luciferase assays.    
2.9 RNA interference and Real Time RT-PCR. 
Cells were sub-cultured into 12-well plates and 24 h later transfected with 50- or 
150 nM of small interfering RNAs (siRNAs) directed against acid ceramidase (ASAH1), 
neutral ceramidase (ASAH2), and alkaline ceramidase (ASAH3), diacylglycerol kinase-
alpha (DAGK-α), diacylglycerol kinase-zeta (DAGK-ζ), diacylglycerol kinase-theta 
(DAGK-θ), phosphoinositide 3-kinase (PI3K), or PTEN, (Dharmacon, Lafayatte, CO) 
using siIMPORTER (Upstate, Lake Placid, NY).  The cells were incubated for 72 h then 
treated with 1 mM Bt2cAMP for 12 h.   
Expression of CYP17 was determined by real time RT-PCR.  For quantitative 
RT-PCR, total RNA was extracted using TRIzol (Invitrogen, Carlsbad, CA) and 
amplified using the iScript One-Step RT-PCR Kit (Bio-Rad, Hercules, CA) on an iCycler 
real-time thermocycler (Bio-Rad, Hercules, CA).  TaqMan probes (Applied Biosystems, 
Foster City, CA) were used to detect CYP17.  PCR reactions were as follows: 1) 1 X 
94ºC, 5 minutes, 2) 45 X 95ºC, 30 seconds, seconds, 52ºC, 45 seconds.  CYP17 
expression was normalized to β-actin (forward 5’-CGGCTCCGGCATGTGCAAG-3’ 
and reverse 5’-TGACGATGCCGTGCTGCATG-3’) and calculated using the delta-delta 




3.1 SF1 binds to sphingolipids under basal conditions. 
We carried out mass spectrometric analysis to identify sphingolipids bound to 
SF1 that was immunoprecipitated from control or cAMP-stimulated H295R cells.   Cells 
were transfected with SF1-pCMV Tag1, treated with Bt2cAMP and immunoprecipitated 
with an anti-SF1 antibody for analysis by LC-ESI-MS/MS.   As shown in Figure 7, LC-
ESI-MS/MS analysis revealed that SPH and lyso sphingomyelin (lysoSM) are bound to 
SF1 isolated from control cells. When treated for 4 h with 1 mM Bt2cAMP, the amount of 
SPH and lysoSM decreases by 44% and 36%, respectively. These findings suggest that 
SPH and/or lysoSM bind to SF1 and maintain the receptor in an inactive conformation 
and that cAMP stimulation decreases sphingolipid binding, thereby activating the 
receptor. The amounts of other sphingolipids (ceramides, sphingomyelin, sphinganine, 
S1P, ceramide-1-Phosphates) were less than 15 pmol/mg total protein. 
3.2 SPH and lysoSM bind SF1 in vitro  
Because LC-ESI-MS/MS analysis of SF1 immunoprecipitated from H295R cells 
does not allow us to determine the stoichiometry of sphingolipid-receptor binding, we 
performed the Scintillation proximity assay (SPA). This assay allows for analysis of the 
interaction between ligand and receptor and for estimation of relative binding affinities. 
The apparent equilibrium dissociation constant (Ki) for SPH and lysoSM was determined 
in competition binding assays. The beads were incubated with 10 nM [3H]SPH in the 
presence of unlabeled SPH or lysoSM at concentrations ranging from 0.1 nM to 100 µM. 
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[3H]SPH specifically bound to SF1 with a calculated Ki of approximately  360 nM, 
confirming LC-ESI-MS/MS studies and further demonstrating that [3H]SPH binds 
directly to SF1. LysoSM on the other hand, had a Ki of approximately 1 µM, was not as 
effective in competing with [3H]SPH for binding to SF1 (Figure 8) 
3.3 Both sphingolipids and phospholipids compete with SPH for binding to SF1. 
Since recent studies have shown that phospholipids are ligands for SF1 and that 
ligand binding is required for maximal activity [23, 24], we determined the ability of 
several phospholipids and sphingolipids to displace SPH using the scintillation proximity 
assay. As shown in Figure 9, most of the lipids tested displace [3H]SPH from the 
receptor.  Phosphatidylinositols (PIPs), which were bound to bacterially expressed SF1 
used for crystallographic studies [23], showed varying abilities to decrease [3H]SPH 
binding to the receptor.  PI(3,4)P2, PI(4,5)P2, and PI(3,4,5)P3 inhibited [3H]SPH binding 
by 40%, 48%, and 57%, respectively, while PI(3,5)P2 only decreased [3H]SPH binding 
by 11%.  PC (16:0-18:1) displaced 78% of [3H]SPH, while PE (16:0-18:1) decreased 
[3H]SPH binding to SF1 by 57%. PA (16:0-18:1) inhibited 82% of [3H]SPH binding to 
SF1, while S1P displaced 93% of labeled SPH 
3.4 Silencing ceramidase induces CYP17 transcription. 
 Based on the SPA competition assays demonstrating that SPH binds to SF1 with a 
higher affinity than lysoSM, we carried out studies to further characterize the role of SPH 
in SF1-dependant CYP17 transcription.  SPH is produced when ceramidases cleave the 
amide bond in ceramide.  To date, three types of ceramidases have been described and 
are classified as acid (ASAH1), neutral (ASAH2) and alkaline (ASAH3) according to the 
pH at which optimal activity is achieved [34-37].  Since we have shown that cAMP 
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decreases the amount of SPH bound to SF1, we hypothesized that decreasing the cellular 
production of SPH would increase CYP17 gene expression.  To test this hypothesis, 
H295R cells were transfected with siRNAs directed against ASAH1, ASAH2, and 
ASAH3 and the mRNA expression of CYP17 was measured by real time RT-PCR.  As 
shown in Figure 10, silencing ASAH1 and ASAH2 increased CYP17 mRNA expression 
by 4.1- and 2.0-fold, respectively, further supporting a role for SPH as an inhibitory 
ligand for SF1. 
3.5 Phosphatidic acid activates SF1 transcriptional activity. 
To determine if any of the lipids that displaced SPH in the scintillation proximity assay 
could activate SF1-dependent CYP17 reporter gene activity, Jeg 3 cells were transfected 
with the CYP17-57pGL3 plasmid and treated with varying concentrations of lipids. None 
of the sphingolipids tested were able to increase SF1-dependent reporter gene activity 
(Figure 11). Jeg3 cells were used because they lack endogenous SF1. As shown in Figure 
12, PA treatment resulted in a dose-dependent increase in CYP17 transcriptional activity 
which was maximal at 100 nM. Based on LC-ESI-MS/MS data demonstrating that cAMP 
treatment decreased the amount of SPH bound to SF1, we hypothesized that SPH may act 
as an antagonist and inhibit the ability of PA to activate SF1-dependent CYP17 reporter 
gene activity. As shown in Figure 12B, increasing concentrations (1- to 25 µM) of SPH 






































Figure 7: SPH & lysoSM binds to SF1 in vivo. 
A, Quantification of LC-ESI-MS/MS analysis of SPH bound to SF1. H295R cells were 
transiently transfected with SF1-pCMVTag1 and treated for 4 h with 1mM Bt2cAMP. 
The lysates were immunoprecipitated with anti-SF1 antibody and the immunoprecipitated 
receptor analyzed by LC-ESI-MS/MS. Structures of SPH 





















Figure 8: SPH binds to the LBD of SF1 in vitro. 
His-tagged SF1 was expressed in E. coli, purified, biotinylated and coupled to 
streptavidin-coated SPA beads as described in Materials and Methods. Competition 
binding assay; Receptor-bound SPA beads were incubated with 10 nM [3H] SPH and 
non-radiolabeled SPH (0.1 nM to 100 µM, filled squares) or lysoSM (0.1 nM to 100 µM, 



















Figure 9: Phospholipids and sphingolipids compete with [3H]SPH for binding to 
SF1. 
The LBD of SF1 was His-tagged, expressed in E. coli, biotinylated and coupled to 
streptavidin-coated SPA beads as described in Materials and Methods. Competition 
binding assays were performed with 10 nM [3H]SPH and 10 µM of each lipid. Data 
represent the mean of three assays performed in triplicate + SD and are plotted as percent 
























Figure 10: Silencing ceramidase expression induces CYP17 mRNA. 
Cells were transfected with siRNA oligonucleotides targeted against ASAH1, ASAH2, or 
ASAH3 for 48 h. One group of untransfected cells was treated with 1 mM Bt2cAMP 
(dbc) for 12 h. Total RNA was isolated and CYP17 mRNA expression was determined 
using real time RT-PCR. Data graphed represents the mean + SEM of 3 separate 






















































Figure 11: None of the sphingolipids inhibiting SPH binding in SPA, increase SF1 
dependent reporter gene activity. 
H295R Cells were transfected with 250 ng CYP1757-pGL3 and 50 ng of SF1-
pCMVTag1 using Gene Juice. Twenty-four hours after transfection, the cells were treated 
with 10µM of all lipids except for S1P (1µM) for 6h. Data in the graph is normalized to 
Renilla activity and is expressed as fold increase over CYP17 57-pGL3. Data graphed 
represents the mean + SEM of at least 3 separate experiments, each performed in 












































Figure 12: PA activates CYP17 transcriptional activity.  
Jeg3 cells were transfected with CYP17 57-pGL3 and SF1-pCMVTag1, then treated with 
1 mM Bt2cAMP or PA (1 nM to 1000nM) for 6 h. B, Cells were transfected with 250 ng 
CYP17 57-pGL3 and 50 ng of SF1-pCMVTag1 using Gene Juice. Twenty-four hours 
after transfection, the cells were treated for 6h with 1 µM PA in the presence and absence 
of SPH (1-, 10- or 25 µM). Data in both graphs is normalized to Renilla activity and is 
expressed as fold increase over CYP17 57-pGL3. Data graphed represents the mean + 
SEM of 3 separate experiments, each performed in triplicate. *, p<0.5 statistically 




3.6 Effect of mutations in the LBD on CYP17-reporter gene activity. 
We next characterized the effect of mutations in the LBD of SF1 on CYP17 
reporter gene expression.  Based on recent structural studies identifying residues that 
contact the ligand [23], we made constructs containing mutations in five amino acid 
residues (H310, G341, K440, Y436, and L452).   Jeg3 cells (lack endogenous SF1) were 
transiently transfected with plasmids containing wild type or mutant SF1 and a plasmid 
containing the first 57 base pairs of the human CYP17 promoter fused to the luciferase 
gene as described previously [33].   Cells were treated for 6 h with 1 mM Bt2cAMP or 10 
nM PA.   As shown in Figure 13, transfection of wild type SF1 resulted in a 5.2-fold 
increase in luciferase activity, which was further stimulated by Bt2cAMP and PA.  
Mutations to histidine-310 and glycine-341 reduced SF1-dependent transcriptional 
activity by 29- and 36%, respectively.  While mutations at Y436 and K440 completely 
attenuated the ability of SF1 to transactivate the CYP17 reporter construct (Figure 13).  
None of the mutant constructs were responsive to Bt2cAMP or PA.  Similar results were 
observed in H295R cells.   
3.7 Mutations in the LBD alter SPH binding in vivo. 
Both wild type and mutant FLAG-tagged constructs were transfected into H295R 
cells and immunoprecipitated for analysis by LC-ESI-MS/MS.   Mutating histidine-310 
to alanine decreased binding of SPH by 21% in control cells, however this mutation 
increased the binding of SPH in cAMP-treated cells compared to the wild type SF1 
purified from cAMP-treated cells (Figure 14).  Similar findings were observed with the 
G341A mutation.  Interestingly, the K440A and Y436A mutants both exhibited 
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approximately a 70% decrease in binding to SPH in control cells (Figure 14).  These 
observations suggest that K440 and Y436 are important for binding SPH and that H310 
and G341 may play a role in the cAMP-stimulated exchange of SPH for a lipid whose 
binding is required for activation of the receptor. Of note, we have previously found that 
cAMP activates sphingolipid catabolism ([38]), thus it is possible that the cAMP-
stimulated change in the cellular content of sphingolipids plays a role in activating SF1. 
3.8 DAG kinase is required for SF1-/cAMP-dependent CYP17 transcription. 
PA can be produced in several ways:  phospholipase D (PLD) catalyzed hydrolysis of 
phosphatidylcholine, acylation of LPA, or phosphorylation of diacylglycerol by DAGK.  
To determine the effect of reducing cellular pools of PA, cells were treated with R59949 
[26, 39, 40] to inhibit DAG kinase.  As shown in Figure 15, R59949 attenuated the ability 
of both SF1 and cAMP to activate CYP17 transcription in a dose-dependent manner, 
suggesting that DAGK catalyzed formation of PA is required for synthesizing the 
activating ligand for SF1.   
To determine if PLD catalyzed production of PA was important for SF1-dependent 
CYP17 transcription, transfected cells were also treated with 0.1% 1-butanol ([41]) for 2 
h, however, this PLD inhibitor had no significant effect on the ability of SF1 to increase 
CYP17 luciferase activity (data not shown).  There are nine mammalian isoforms of 
DAGK, most of which have been detected in the nucleus of various tissues and cell lines 
[42, 43].   To further characterize the role of DAG kinases in mediating cAMP-dependent 
CYP17 mRNA expression, H295R cells were transfected with siRNAs targeted at 
DAGK-θ.  Seventy-two h after transfection, the cells were treated with 1 mM Bt2cAMP 
for 12 h and CYP17 mRNA analyzed by real time RT-PCR.  As shown in Figure 16, 
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silencing DAGK-θ expression inhibited the ability of Bt2cAMP to stimulate CYP17 
mRNA expression, while reducing the expression of DAGK-α or DAGK-ζ had no effect 
on cAMP-stimulated CYP17 transcription. 
Because PI3K has been shown to regulate the activity of DAGK-θ ([44]), RNAi 
was used to examine the roles of PI3K and PTEN in cAMP-dependent CYP17 mRNA 
expression.  As shown in Figure 18, silencing PI3K expression significantly inhibits 
cAMP-stimulated CYP17 mRNA expression.  No role was found for PLDs in mediating 
cAMP-dependent CYP17 transcription (data not shown).  These RNAi studies 
demonstrate that cAMP-dependent transcription of CYP17 in H295R cells requires the 
activation of both PI3K and DAG kinase-θ.  Taken together, our studies indicate that 
cAMP activates CYP17 gene expression by promoting the exchange of an inhibitory lipid 































Figure 13: LBD mutants of SF1 show reduced transcriptional activity. 
Jeg3 cells were transiently transfected with 250 ng CYP17 57-pGL3, and 100 ng wild 
type or mutant SF1 (in pCMV Tag1 vector) and treated with 1 mM Bt2cAMP or 10 nM 
PA for 6 h. Data is normalized to the luciferase activity of the Renilla gene and is 
expressed as the fold increase over the CYP17 57- pGL3 plasmid. Data graphed 
represents the mean + the standard error from 4 separate experiments, each performed in 
triplicate. Data graphed represents the mean + SEM of 4 separate experiments, each 


































H310A G341A K440A Y436A
 
Figure 14: Effect of mutations in the LBD of SF1 on SPH binding in vivo. 
A, Cells were transiently transfected with wild type or mutant SF1 and treated for 4 h 
with 1mM Bt2cAMP. A, The lysates were immunoprecipitated with anti-FLAG antibody 
and sphingolipid binding analyzed by LC-ESI-MS/MS. SPH amounts are expressed in 
pmol/mg total protein and determined by comparison to a standard. B, Expression of wild 
type and mutant receptor in transfected H295R cells. A fraction (10 µl of a 50% slurry) of 















Figure 15: DAG kinase inhibition attenuates cAMP-stimulated CYP17 transcription 
activity. 
H295R cells were transiently transfected with CYP17 57-pGL3 and SF1-pCMVTag1, 






































Figure 16: cAMP-dependent CYP17 transcription requires DAGK-θ. 
 Cells were transfected with 150 nM siRNAs directed against DAGK-α, DAGK-θ, or 
DAGK-ζ for 72 h, then treated with 1 mM Bt2cAMP for 12 h. Total RNA was extracted 
and real time RT-PCR was performed. CYP17 mRNA expression was normalized to 
actin content. Values graphed represent the mean + SEM of 3 separate experiments, each 




























































Figure 17: Effect of RNAi on DAGK protein expression.  



































Figure 18: cAMP-stimulated CYP17 mRNA expression requires PI3K. 
A, H295R cells were transfected with 150 nM siRNAs directed against PI3K or PTEN 
for 96 h, then treated with 1mM Bt2cAMP for 12 h. Total RNA was extracted and real 
time RT-PCR performed to determine CYP17 mRNA expression. CYP17 mRNA 
expression was normalized to actin content. Values graphed represent the mean + SEM of 
at least 3 separate experiments, each performed in at least triplicate. *, p<0.5 statistically 





Figure 19: Knockdown of PI3K and PTEN protein expression using siRNA 
oligonucleotides. 






Nuclear receptors function as ligand activated transcription factors that regulate the 
expression of target genes to affect processes as diverse as reproduction, development, 
and general metabolism [45-48]. Orphan nuclear receptors, lack identified ligands, and 
hence provide a unique, and largely untapped, resource to discover new principles of 
physiologic homeostasis, and it is required for development of endocrine glands and 
sexual development [49, 50].  Several classes of lipids, including sterols, retinoids, fatty 
acids, and lipophilic xenobiotics, have been identified as ligands for orphan nuclear 
receptors [45].  Recently, crystallographic studies of bacterially expressed SF1 have 
identified another important class of lipids, phospholipids, as ligands for SF1 [23-25].  
In the current study we used LC-ESI-MS/MS to identify ligands bound to SF1 
endogenously expressed in H295R human adrenocortical cells and to characterize the 
effect of cAMP on the ability of these ligands to bind to SF1.  SF1 is essential for steroid 
hormone biosynthesis and for the expression of steroidogenic genes.  In the adrenal 
gland, steroidogenic gene transcription occurs in response to ACTH, a peptide hormone 
that binds to G protein-coupled receptors on the surface of adrenocortical cells and 
activates a cAMP signal transduction cascade [51].  Increased intracellular cAMP results 
in the activation of the PKA, and ultimately the coordinate increase in the transcription of 
steroidogenic genes.  The direct target of PKA has yet to be determined, however several 
transcription factors, including SF1, are required for conveying cAMP-dependent 
transcription [51]. 
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Mutation of A270W in murine SF1 reduces its ability to bind these phospholipids 
and the transcriptional activity of this ligand binding pocket mutant is also reduced as 
compared to wild type murine SF1 [23].  Mutagenesis studies carried out by Li et al., in 
HEPG2 cells demonstrate that among amino acids L266W, A270W, L348W, V349W, 
A352W, A434W, K441E, the mutation K441E has a severe effect as it disrupts the 
specific hydrogen bonds with bound phospholipids [24].  Our reporter gene studies in 
Jeg3 cells, which lack endogenous SF1 (Figure 13) as well as in H295R human 
adrenocortical cells (data not shown) with SF1 containing mutations in the ligand binding 
pocket reveal that H310, G341, Y436, and K440 are critical for basal, cAMP, and PA-
stimulated transactivation potential.  Based on modeling studies, the reduction in activity 
observed with the K440 mutant is due to the inability of the phosphate moiety on PA to 
interact with the positively charged lysine.  Glycine-341 is important for packing, thus 
increasing the size of this residue negatively impacts the ability of the receptor to bind 
PA.  Based on the amount of SPH bound to the H310A and G341A mutants’ 
immunoprecipitated from Bt2cAMP-treated cells (Figure 14), we speculate that mutation 
of these two residues increases the stability of SPH in the binding pocket and prevents 
exchange of SPH for PA. 
Our findings demonstrate that SF1 is a lipid binding protein.  Specifically, we 
have shown that SPH is bound to SF1 immunoprecipitated from H295R cells (Figure 7).  
Importantly, the amount of SPH bound to SF1 is regulated by cAMP because SF1 
purified from cells exposed to Bt2cAMP contained decreased amounts of SPH.  These 
findings suggest that SPH is an inhibitory ligand for SF1 and that activation of the 
receptor takes place by the exchange of SPH for an activating ligand.  This hypothesis is 
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supported by siRNA data demonstrating that silencing the expression of acid and neutral 
ceramidases increases CYP17 mRNA expression (Figure 10).  SPH is not synthesized de 
novo [52, 53], thus the sole cellular source of SPH is through the hydrolysis of ceramide; 
a reaction catalyzed by ceramidases [34-36]. Acid ceramidase has a pH optimum of 
approximately 4.5, thus the hydrolytic activity of this enzyme is thought to occur within 
lysosomes and/or late endosomes, whereas neutral and alkaline ceramidases are active at 
pH values ranging from 6.5 to 9.0 [54].  Studies using cloned neutral and alkaline 
ceramidases have shown that these enzymes can catalyze both the forward and reverse 
reactions (ceramide degradation and synthesis) in vitro [55-57].  The neutral ceramidase 
is membrane-bound; however, it has yet to be determined whether this enzyme is 
associated with the nuclear membrane.  Of note, studies have shown that PA and 
phosphatidyl serine stimulate the hydrolytic activity of neutral ceramidase [58].  Based 
on our current findings, it is plausible that PA may serve as a feedback inhibitor of SF1-
dependent transcription by stimulating the production of SPH, the inhibitory ligand.   
Scintillation proximity assays demonstrated that several phospholipids and 
sphingolipids compete with radiolabeled SPH for binding to SF1 (Figure 9).  Of the lipids 
that displaced SPH from the ligand binding pocket, only PA significantly induced SF1-
dependent CYP17 reporter gene activity.  Further, studies using chemical inhibitors and 
RNAi found that the enzyme important for PA production in H295R cells is DAGK-θ.  
DAGK-θ has been found localized in speckle domains of nuclei from various cell lines 
[59].  Nuclear DAGK-θ co-localized with PI(4,5)P2, suggesting coupling of PIP2 
hydrolysis and PA formation [59].  Both DAGK-α [60] and DAGK-θ [44] are regulated 
by PI3K.  Our findings that silencing PI3K protein expression significantly reduces 
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cAMP-stimulated CYP17 mRNA expression (Figure 18) support a relationship between 
DAGK and PI3K.  Studies are underway to characterize the mechanism by which 
cAMP/PKA regulate PI3K activity in H295R cells.  Interestingly, SPH increases nuclear 
PA formation, likely by stimulating DAG kinase activity [61].  In light of our current 
findings, we propose that SPH and PA may reciprocally activate the synthesis of each 
other.  In the presence of cAMP, the conformation of SF1 is changed to allow 
dissociation of SPH.  Once dissociated from SF1, SPH then acts to augment DAG kinase 
activity, thereby increasing production of PA, which in turn stimulates SF1-dependent 
transcriptional activity.  To terminate SF1-dependent transcription, PA may act as a 
feedback inhibitor by stimulating ceramidase activity.  Using LC-ESI-MS/MS, we have 
also found that PA is bound to SF1 purified from H295R cells (unpublished data), 
however further studies are needed to quantify the amounts of PA bound to the receptor 
and to determine the effect of cAMP on the amounts of PA in nucleus.   
As previously discussed, both recently published crystal structures have revealed 
that SF1 contains a large ligand binding pocket which is filled by a phospholipid ligand 
[23, 24].  Li et al., show that the interaction of SF1 with coactivators is reduced both by 
the absence of phospholipids and by phospholipids with longer fatty acids, longer acyl 
chains are predicted to project out of the pocket and interfere with the folding of the AF-2 
helix into the active conformation [24].  Although both studies identified different 
phospholipids in the SF1 ligand binding pocket, neither study showed the presence of 
SPH.  This is because bacteria do not synthesize sphingolipids.  Further, in both structural 
studies, bacterially expressed SF1 was used to identify the phospholipid ligands, whereas 
in the present study, we immunoprecipitated SF1 from H295R adrenocortical cells and 
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subjected the purified receptor to analysis by LC-ESI-MS/MS.   Thus, our findings 
provide physiologically relevant confirmation of the recently published crystallographic 
studies.  Additionally, our findings demonstrate a mechanism by which cAMP can 
activate the exchange of an inhibitory ligand (SPH) for a stimulatory ligand (PA).  As the 
ligand binding pocket of SF1 is large, it is likely that SF1 has multiple ligands.  Our 
scintillation proximity assay data showing that several phospholipids can compete with 
SPH for binding suggest that SF1 may respond to different lipids in a context-specific 
manner to direct the expression of genes involved in development and steroidogenesis.   
Our findings, showing cAMP-stimulated decreases SPH binding to SF1 (Figure 7) 
are in agreement with the prediction of Li et al., that SF1 readily exchanges its ligands 
[24].  It is plausible that cAMP alters lipid amounts in distinct organelles (such as the 
nucleus) and that these changes are essential for steroidogenic gene transcription.  Studies 
are underway to determine the effect of cAMP on the subcellular populations of 
phospholipids and sphingolipids.  In summary, our findings demonstrate a mechanism by 
which SPH and PA act in a reciprocal manner as inhibitory and stimulatory ligands for 
SF1, respectively.  We propose that ACTH/cAMP activates CYP17 in the human adrenal 







1. Treat for appropriate time with agent/stimulus 
 
2. Wash cells twice with 8 ml PBS 
 
3. Add 1 ml RIPA buffer with 1X protease inhibitors 
 
4. Scrape plate into clean microfuge tube 
 
5. Incubate on ice for 30 minutes 
 
6. Sonicate 10 times for 5 seconds each , keep samples cold at all times 
 
7. Spin at full speed for 15 minutes at 4ºC 
 
8. Transfer supernatant to a clean tube and pre-clear by adding: 
 
9. 20 µl protein A/G agarose 
10. 1 µg of IgG (If primary antibody is rabbit then use rabbit IgG. If antibody is 
raised in mouse, use mouse IgG) 
 
11. Rotate for 30 minutes at 4ºC 
 
12. Spin at full speed for 15 minutes at 4ºC 
 
13. Transfer supernatant to a clean tube and add: 
 
1-10 µl primary antibody (SF1, PP2A, etc) 
25 µl protein A/G agarose 
10µl BSA (20mg.ml) 
 
14. Rotate overnight at 4ºC 
 
15. Spin at 4000 rpm for 5 minutes 
 
16. Remove supernatant and wash beads for 5 minutes 
2x with RIPA buffer 
2x with PBS 
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17. Add 30 µl SDS loading dye to each sample 
 
18. Boil 5 minutes, cool on ice for 5 minutes 
 
19. Load samples onto SDS/PAGE gel 
 
SDS Poly-Acrylamide Gel 
 
1. Resolving Gel (10 %, 10 ml): 
a. 4.0 ml H2O 
b. 3.3 ml 30 % acrylamide 
c. 2.5 ml 1.5 M Tris, pH 8.8 
d. 0.1 ml 10 % SDS 
e. 0.1 ml 10 % ammonium persulfate 
f. 0.004 ml TEMED 
2. Load gel. 
3. Pour 30 % ethanol on top of gel 
4. Stacking Gel (5%, 4 mL): 
a. 2.7 ml H2O 
b. 0.67 ml 30 % acrylamide 
c. 0.5 ml 1.5 M Tris, pH 6.8 
d. 0.04 ml 10 % SDS 
e. 0.04 ml 10 % ammonium persulfate 
f. 0.004 ml TEMED 




1. Prepare loading buffer: 
2X SDS gel loading buffer: 1M DTT:: 9: 1 
2. Prepare a mixture of equal volumes of loading buffer and samples depending 
on the size of the wells (small:15-20 µL per well, large:30-40 µL per well) 
3. Heat samples at 100oC (incubator ~4) for 5 minutes.  Put a hole on top of each 
tube.   








Running the Gel 
 
1. Use protein markers. 
2. Use 1X SDS-PAGE buffer. 
3. Run the gel at 50-60 V.   
4. When the bands reach the resolving gel, turn the voltage up to 100-120 V. 
 
Transferring the Gel 
  
1. Use Western Blot Buffer (100 mL): 
a. 0.025 M Tris base (2.5 mL 1M Tris, pH 8) 
b. 0.192 M glycine (1.441 g) 
c. 20 % methanol (20 mL) 
d. pH 8.3 
2. Place three pre-soaked sheets of filter paper on bottom. 
3. Place membrane soaked in methanol on top. 
4. Place three additional sheets of filter paper on top. 
5. Transfer the gel at 100 mA for 30 minutes. 





























All at room temperature 
I.    Electrophoresis and blotting 
• Pre-treat PVDF membrane  
• In methanol for 5 second  
• In water for 5 minutes 
• In transfer buffer for 10-15 minutes 
• Separate proteins using SDS-PAGE electrophoresis and electroblotting on 
to Hybond P (PVDF) membrane 
 
II.      Blocking Membrane 
• Immerse membrane in 5% (w/v) blocking agent in PBS-T for one hour on 
orbital shaker at room temperature 
 
III.    Washing 
• Dilute primary antibody in PBS-T  
• On orbital shaker wash twice for 2 minutes with large volume of PBS-T 
(fresh washing buffer in-between) 
• On orbital shaker wash 2 times for 15 minutes each with large volume of 
PBS-T (fresh washing buffer in-between) 
• On orbital shaker wash 2 times for 5 minutes each with large volume of 
PBS-T (fresh washing buffer in-between) 
 
IV.    Incubation 
• Incubate membrane in diluted primary antibody for 1 hour on orbital 
shaker 
 
V.    Dilution of fluorecein-linked anti-species antibody 
• Dilute fluorescein-linked anti-mouse Ig for pERK or anti-rabbit Ig for ERK 
1:2000 in PBS-T 
 
VI. Washing 
• On orbital shaker wash twice for 2 minutes with large volume of PBS-T 
(fresh washing buffer in-between) 
• On orbital shaker wash 2 times for 15 minutes each with large volume of 
PBS-T (fresh washing buffer in-between) 
• On orbital shaker wash 2 times for 5 minutes each with large volume of 
TBS-T or PBS-T (fresh washing buffer in-between) 
 
VII. Incubation 
• Incubate membrane in diluted secondary antibody for 1 hour on orbital 
shaker 
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VIII. Dilution of Anti-fluorescein alkaline phosphotase conjugate 
• Dilute anti-fluorescein AP conjugate 1:2500 with PBS-T  
 
IX.    Washing 
• On orbital shaker wash twice for 2 minutes with large volume of PBS-T 
(fresh washing buffer in-between) 
• On orbital shaker wash 2 times for 15 minutes each with large volume of 
PBS-T (fresh washing buffer in-between) 
• On orbital shaker wash 2 times for 5 minutes each with large volume of 
PBS-T (fresh washing buffer in-between) 
 
X.  Incubation 
• Incubate membrane in diluted conjugate for 1 hour on orbital shaker at 
room temperature 
 
XI.  Washing  
• On orbital shaker wash twice for 2 minutes with large volume of PBS-T 
(fresh washing buffer in-between) 
• On orbital shaker wash 2 times for 15 minutes each with large volume of 
PBS-T (fresh washing buffer in-between) 
• On orbital shaker wash 2 times for 5 minutes each with large volume of 
PBS-T (fresh washing buffer in-between) 
      
       XII       Cover the membrane with ECF and incubate for 20 mins. 
 
       XIII      Let the excess ECF drain, and then incubate the membrane in dark for 
        20min. 
 




















Trizol RNA Preparation 
Wash cells 2x with PBS 
 
Add 500µl Trizol to each well and scrape into 1.5ml tubes 
 
Incubate at room temperature for 5 minutes 
 
Add 100µl chloroform/ iso amy 
 
Shake for 20 seconds 
 
Incubate at room temperature for 3 minutes 
 
Spin at 12,000 rpm for 15 minutes at 4ºC 
 
Remove aqueous phase (clear) to new tube 
 
Add 200µl isopropanol 
 
Incubate at room temperature for 10 minutes 
 
Spin at 12,000 rpm 4ºC for 10 minutes 
 
Remove supernatant and add 500µl 75% ETOH 
 




Air dry 15-30 minutes at room temperature 
 















siIMPORTER Protocol For RNA Interference 
 
1. change Media according to Table 1 
 
Table 1: 
FORMAT MEDIA (µl) siRNA/siIMPORTER 
(µl) 
TOTAL (µl) 
12 well 465 35 500 
6 well 930 70 1000 
 
 
2. in microcentrifuge tude add siIMPORTER and RPMI based on Table for a whole 12 
well plate: 
siIMPORTER vol. = 2.5 • 12 wells = 30 µl 




 PER WELL 
FORMAT SiIMPORTER (in µl)                                RPMI (in µl) 
12 WELLS               2.5                                                              12.5 
6 WELLS                 5                                                                 25 
 
 
3. mix by pipetting 
4. in another microcentrifuge tube mix diluent, RPMI  and siRNA according to table 3 
(this will give a 100 nM/ well) 
Table 3: 
 
FORMAT Diluent (µl) RPMI (µl) siRNA (µl) 
12 well 12.5 5 2.5 
6 well 25 10 5 
 
 
5. mix by pipetting 
6. add step 4 to step 2 
7. incubate for 5-10 mininutes and add 35µl dropwise to each well 
 50
 
Site Directed Mutagenesis 
PCR reactions: 50ul run 
 
 10x Pfu buffer 
 10 mM dNTP’s 
 DMSO 
 50ng template 
 125 ng forward primer 




Cycles:  x16 
30 sec @ 95ºC 
1 min @ 55ºC 
10 minutes @ 68ºC 
Add 2µl Dpn1 to reaction and incubate @ 37ºC for 1 hour 
Perform gel electrophoresis on 20µl of sample. 
Transformation:  
Add 2µl (or more if necessary) PCR reaction to 50µl XL1 blue cells 
Incubate on ice for 30 mininutes 
Heat shock at 42ºC for 1 minutes 
Incubate on ice for 5 minutes 
Add 500µl LB 
Incubate @ 37ºC for 1 hr with constant shaking 
Plate on selective media 
Select colonies & grow up overnight 












Wash cells twice with PBS 
Remove PBS completely 
Prepare Passive Lysis Buffer (Promega) by Diluting 5x stock with H2O 
(1 part 5x: 4 parts Water) 
Add 100µl Passive Lysis Buffer to each well 
Place plates in –80ºC for 10-20 minutes 
Place plates in 37 degree water bath for approximately 1 minute (until contents in all 
wells have melted) 
Repeat freeze/thaw cycle twice 
Thaw appropriate volumes of Dual Luciferase Assay (Promega) and Stop and Glo 
Reagents 
Luciferase Assay Reagent 100ul/sample 
Stop and Glo Reagent 100ul/sample 
(Dilute Stop and Glo Substrate 1 part:  Stop and Glo Buffer 49 parts) 
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